Rebif Ready For Antegren Following MS Market Share Gains, Serono Says

Serono is confident that Rebif can compete against Elan/Biogen Idec's Antegren both on mechanism of action and indication; Antegren's estimated user fee deadline is in November. Rebif gains share against Biogen Idec's Avonex and Berlex' Betaseron, reaching 12-month rolling sales of $1 bil.